FCE
AEGR

Fiera Capital (Europe)’s Aegerion Pharmaceuticals AEGR Stock Holding History

Fiera Capital (Europe)’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-4,362
Closed -$83K – 57
2015
Q2 		$83K Sell
4,362
-5,279
-55% -$114K 0.08% 46
2015
Q1 		$252K Hold
9,641
– – 0.23% 30
2014
Q4 		$202 Buy
+9,641
New +$243K 0.15% 33

Other funds holding AEGR

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fiera Capital (Europe)'s AEGR Position: Q3 2015 in Review

Fiera Capital (Europe) sold out of Aegerion Pharmaceuticals (AEGR) in Q3 2015, closing a stake of 4,362 shares — an estimated $83K sold.

Fiera Capital (Europe) first reported a position in AEGR in Q4 2014 and held it in 3 quarters. The position peaked at $252K in Q1 2015. 96 funds tracked by Wall St. Rank hold AEGR as of Q3 2015.

  • Fiera Capital (Europe) reported no remaining Aegerion Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Fiera Capital (Europe) sold 4,362 Aegerion Pharmaceuticals shares in Q3 2015, an estimated $83K.
  • Fiera Capital (Europe) first reported a position in Aegerion Pharmaceuticals in Q4 2014 and held it in 3 quarters.
  • Fiera Capital (Europe)'s Aegerion Pharmaceuticals position peaked at $252K in Q1 2015.
  • 96 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q3 2015.

Based on Fiera Capital (Europe)'s 13F filing for Q3 2015, filed 9 Nov 2015.